Skip to main content

Tweets

Anti- neutrophil extracellular traps (NET) Abs were elevated in 328 COVID-19 pts, 27% IgG & 60% IgM. Net Abs assoc w/ circulating NETs, impaired O2 ventilation, high D-dimers. They likely impair NET clearance and may worsen thromboinflammation. https://t.co/xRNKqKjxzS

Dr. John Cush @RheumNow ( View Tweet )

5 years ago
NEJM Image: Salt-and-Pepper Skin Changes in Systemic Sclerosis. 68yoM with skin changes of chest and back and with shortness of breath. Exam:showed “salt-and-pepper” skin changes, w/ CT evidence of lung fibrosis. https://t.co/Pz7mKUD2Yx

Dr. John Cush @RheumNow ( View Tweet )

5 years ago
A study of 7459 adults with diabetes, shows that regular bicycling is associated with a 22-32% reduction in all cause mortality and CVD mortality - with a loss of benefit to those who stop. https://t.co/wjEJXAu0zx

Dr. John Cush @RheumNow ( View Tweet )

5 years ago
In a study of 15123 RA pts >50 yrs; 1640 osteoporotic fractures occurred. Low-dose glucocorticoids (≤7.5 mg/D) was not associated with overall risk of OP Fx (adj HR 1.14) but was assoc w/ increased risk of vertebral Fx (adj HR 1.59, 1.11–2.29) https://t.co/ZJtYAAQ3KW

Dr. John Cush @RheumNow ( View Tweet )

5 years ago
EULAR guidelines rec starting prednisone dose in #PMR to be between 12.5-25mg/d. A cross sectional study of 138 pts (63M, 75F, age 73.4 yes) saw the mean starting dose to be 19.2±7.7 mg.  https://t.co/Yf3yqRRMCK

Dr. John Cush @RheumNow ( View Tweet )

5 years ago
US life expectancy dropped by 1.5 years in 2020, driven by the pandemic. https://t.co/89i333vmPv

Dr. John Cush @RheumNow ( View Tweet )

5 years ago
#VaccinationCovid DOES induce #SARS_CoV_2-specific #antibodies in #Rituximab-treated patients, after peripheral B-cells have at least partially repopulated! In addition, T cell responses (independent of B cell status) may also exert protective effects! https://t.co/E1FErHJtd3

Daniel Aletaha @DanielAletaha ( View Tweet )

5 years ago
Canakinumab Fails to Improve COVID-19 Survival https://t.co/ngThAgfHTq JAMA has published the findings of trial wherein the anti–interleukin-1β antibody canakinumab (CAN) failed to improve survival patients hospitalized with severe COVID-19. https://t.co/pUBmt85jAC
Dr. John Cush @RheumNow ( View Tweet )
5 years ago
Metanalysis of 39 studies, 15,673 pts with nail psoriasis = 100% improvement of the Nail Psoriasis Severity Index, ixekizumab was best @ 24 wks (OR 2.98; 95% CI, 1.74-5.10), followed by TNF inhibitor (infliximab, adalimumab). https://t.co/VnhbMPYEV7

Dr. John Cush @RheumNow ( View Tweet )

5 years ago
Drugs capable of inducing drug-associated ANCA vasculitis - mirabegron (Myrbetriq), sofosbuvir (Sovaldi, antiviral), nintedanib (Ofev), hydralazine, propylthiouracil, thiamazole, minocycline, carbimazole, allopurinol, influenza vax.... https://t.co/KhK2w10hs5

Dr. John Cush @RheumNow ( View Tweet )

5 years ago
FDA delays in the analysis of Pfizers/Xeljanz Oral Surveillance Safety study has put off potential approvals for other JAKs (Lillys Oluminant in Eczema & Abbvies Rinvoq for Eczema, Psoriatic arthritis, Ank Spondylitis). The wait continues.. https://t.co/3pRp2Vnuhw

Dr. John Cush @RheumNow ( View Tweet )

5 years ago
ICYMI: 263 RA patients with ILD were treated w/ Abatacept (ABA mono, ABA+MTX or ABA+nonMTX) - all improved their DAS28, stabilized their FVC, DLCO, Chest CT; Only difference was that steroid sparing best when ABA used in combo. https://t.co/1dGufcsRpC

Dr. John Cush @RheumNow ( View Tweet )

5 years ago
×